Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Atypical acute motor axonal neuropathy following alemtuzumab treatment in multiple sclerosis patient.

Hradilek P, Woznicova I, Slonkova J, Lochmanova A, Zeman D.

Acta Neurol Belg. 2017 May 31. doi: 10.1007/s13760-017-0799-2. [Epub ahead of print] No abstract available.

PMID:
28567571
2.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

PMID:
28002679
3.

Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting.

Zeman D, Kušnierová P, Švagera Z, Všianský F, Byrtusová M, Hradílek P, Kurková B, Zapletalová O, Bartoš V.

PLoS One. 2016 Nov 15;11(11):e0166556. doi: 10.1371/journal.pone.0166556. eCollection 2016.

4.

Quantitation of free light chains in the cerebrospinal fluid reliably predicts their intrathecal synthesis.

Zeman D, Kušnierová P, Bartoš V, Hradílek P, Kurková B, Zapletalová O.

Ann Clin Biochem. 2016 Jan;53(Pt 1):174-6. doi: 10.1177/0004563215579110. Epub 2015 Mar 9.

PMID:
25753032
5.

Oligoclonal free light chains in cerebrospinal fluid as markers of intrathecal inflammation. Comparison with oligoclonal IgG.

Zeman D, Hradilek P, Kusnierova P, Piza R, Reguliova K, Woznicova I, Zapletalova O.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):104-13. doi: 10.5507/bp.2014.058. Epub 2014 Dec 5.

6.

Incidence of the urological tumours in patients suffering from multiple sclerosis.

Krhut J, Hradilek P, Nemec D, Tvrdik J, Zapletalova O, Zvara P.

Acta Neurol Scand. 2014 Sep;130(3):193-6. doi: 10.1111/ane.12264. Epub 2014 May 8.

PMID:
24810630
7.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators.

Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.

PMID:
24794721
8.

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; ALLEGRO Study Group.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851-8. doi: 10.1136/jnnp-2013-306132. Epub 2013 Sep 12.

PMID:
24029546
9.

Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.

Hradilek P, Zeman D, Tudik I, Zapletalova O, Ulmann V.

Mult Scler. 2014 Apr;20(5):639-40. doi: 10.1177/1352458513501572. Epub 2013 Aug 19. No abstract available.

PMID:
23959714
10.

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group.

N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318.

11.

Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern.

Zeman D, Hradílek P, Svagera Z, Mojžíšková E, Woznicová I, Zapletalová O.

Fluids Barriers CNS. 2012 Feb 23;9(1):5. doi: 10.1186/2045-8118-9-5.

12.

Distal enlargement of the optic nerve sheath in the hyperacute stage of intracerebral haemorrhage.

Skoloudík D, Herzig R, Fadrná T, Bar M, Hradílek P, Roubec M, Jelínková M, Sanák D, Král M, Chmelová J, Herman M, Langová K, Kanovsky P.

Br J Ophthalmol. 2011 Feb;95(2):217-21. doi: 10.1136/bjo.2009.172890. Epub 2010 Aug 1.

PMID:
20679081
13.

Transcranial duplex sonography and CT angiography in acute stroke patients.

Bar M, Skoloudík D, Roubec M, Hradílek P, Chmelová J, Czerný D, Procházka V, Langová K, Herzig R.

J Neuroimaging. 2010 Jul;20(3):240-5. doi: 10.1111/j.1552-6569.2008.00358.x. Epub 2009 Feb 13.

PMID:
19226339
14.

Colour Doppler imaging evaluation of blood flow parameters in the ophthalmic artery in acute and chronic phases of optic neuritis in multiple sclerosis.

Hradílek P, Stourac P, Bar M, Zapletalová O, Skoloudík D.

Acta Ophthalmol. 2009 Feb;87(1):65-70. doi: 10.1111/j.1755-3768.2008.01195.x. Epub 2008 Jun 19.

15.

Safety and efficacy of the sonographic acceleration of the middle cerebral artery recanalization: results of the pilot thrombotripsy study.

Skoloudik D, Bar M, Skoda O, Vaclavik D, Hradilek P, Allendoerfer J, Sanak D, Hlustik P, Langova K, Herzig R, Kanovsky P.

Ultrasound Med Biol. 2008 Nov;34(11):1775-82. doi: 10.1016/j.ultrasmedbio.2008.04.002. Epub 2008 Jun 5.

PMID:
18538464
16.

Analysis of the upper urinary tract function in multiple sclerosis patients.

Krhut J, Hradílek P, Zapletalová O.

Acta Neurol Scand. 2008 Aug;118(2):115-9. doi: 10.1111/j.1600-0404.2008.00992.x. Epub 2008 Feb 25.

PMID:
18307573
17.

Distribution and elimination of o-125I-benzoate in rats.

Láznícek M, Kvĕtina J, Srámek B, Kronrád L, Hradílek P.

Gen Physiol Biophys. 1983 Aug;2(4):279-85.

PMID:
6678770

Supplemental Content

Loading ...
Support Center